{"pmid":32414522,"title":"Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19).","text":["Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19).","COVID-19 is a global public health emergency with more than one million positive cases across the globe. COVID-19 has a multifaceted presentation. We are herein to report two cases of SARS-CoV-2 induced rhabdomyolysis with an initial presentation of weakness and elevated creatinine kinase (CK). Both patients had no respiratory symptoms, they only complained of generalized weakness and were found to have elevated CK. Routine chest X-ray showed bilateral infiltrates in both cases and subsequently reverse-transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 was positive. To the best of our knowledge, there was only one literature to date documented SARS-CoV-2 induced rhabdomyolysis as a late complication of COVID-19 patient. Our cases showed that elevated CK and rhabdomyolysis can be the sole initial presentation of patients with COVID-19 and total CK should be ordered in every patient on admission.","Am J Emerg Med","Chan, Kok Hoe","Farouji, Iyad","Abu Hanoud, Amany","Slim, Jihad","32414522"],"abstract":["COVID-19 is a global public health emergency with more than one million positive cases across the globe. COVID-19 has a multifaceted presentation. We are herein to report two cases of SARS-CoV-2 induced rhabdomyolysis with an initial presentation of weakness and elevated creatinine kinase (CK). Both patients had no respiratory symptoms, they only complained of generalized weakness and were found to have elevated CK. Routine chest X-ray showed bilateral infiltrates in both cases and subsequently reverse-transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 was positive. To the best of our knowledge, there was only one literature to date documented SARS-CoV-2 induced rhabdomyolysis as a late complication of COVID-19 patient. Our cases showed that elevated CK and rhabdomyolysis can be the sole initial presentation of patients with COVID-19 and total CK should be ordered in every patient on admission."],"journal":"Am J Emerg Med","authors":["Chan, Kok Hoe","Farouji, Iyad","Abu Hanoud, Amany","Slim, Jihad"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32414522","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.ajem.2020.05.015","keywords":["covid-19","elevated creatinine kinase","rhabdomyolysis","sars-cov-2"],"e_drugs":["Creatinine"],"topics":["Case Report"],"weight":1,"_version_":1666991242668408832,"score":9.490897,"similar":[{"pmid":32447505,"title":"Pediatric COVID-19-associated rhabdomyolysis: a case report.","text":["Pediatric COVID-19-associated rhabdomyolysis: a case report.","COVID-19 is the illness caused by infection with the novel coronavirus SARS-CoV-2. Although myalgia is common in adults, it has not been noted as a common symptom in children. There have been a few reported cases of COVID-19-associated rhabdomyolysis in adults. This case report describes a 16-year-old boy who presented with fever, myalgias, mild shortness of breath with exertion, and dark-colored urine. COVID-19 PCR was positive. His initial creatinine kinase (CK) level was 427,656 U/L. Serum creatinine was normal for age. He was treated with isotonic intravenous fluids containing sodium bicarbonate to maintain urine output of 100-200 mL/h and urine pH > 7.0. His serum creatinine remained normal throughout the hospital stay and he was discharged on hospital day 12 with a CK of 6526 U/L. To our knowledge, no pediatric cases of COVID-19-associated rhabdomyolysis have been previously reported. Adult cases of rhabdomyolysis have been reported and a few reports have noted patients with elevated CK levels without rhabdomyolysis. Given this pediatric case of COVID-19-associated rhabdomyolysis, pediatric clinicians should be aware of this complication and manage fluids appropriately in order to prevent acute kidney injury.","Pediatr Nephrol","Gefen, Ashley M","Palumbo, Nancy","Nathan, Suresh K","Singer, Pamela S","Castellanos-Reyes, Laura J","Sethna, Christine B","32447505"],"abstract":["COVID-19 is the illness caused by infection with the novel coronavirus SARS-CoV-2. Although myalgia is common in adults, it has not been noted as a common symptom in children. There have been a few reported cases of COVID-19-associated rhabdomyolysis in adults. This case report describes a 16-year-old boy who presented with fever, myalgias, mild shortness of breath with exertion, and dark-colored urine. COVID-19 PCR was positive. His initial creatinine kinase (CK) level was 427,656 U/L. Serum creatinine was normal for age. He was treated with isotonic intravenous fluids containing sodium bicarbonate to maintain urine output of 100-200 mL/h and urine pH > 7.0. His serum creatinine remained normal throughout the hospital stay and he was discharged on hospital day 12 with a CK of 6526 U/L. To our knowledge, no pediatric cases of COVID-19-associated rhabdomyolysis have been previously reported. Adult cases of rhabdomyolysis have been reported and a few reports have noted patients with elevated CK levels without rhabdomyolysis. Given this pediatric case of COVID-19-associated rhabdomyolysis, pediatric clinicians should be aware of this complication and manage fluids appropriately in order to prevent acute kidney injury."],"journal":"Pediatr Nephrol","authors":["Gefen, Ashley M","Palumbo, Nancy","Nathan, Suresh K","Singer, Pamela S","Castellanos-Reyes, Laura J","Sethna, Christine B"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447505","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00467-020-04617-0","keywords":["children","coronavirus","creatine kinase","sars-cov-2"],"locations":["myalgia"],"topics":["Case Report"],"weight":1,"_version_":1667698385922031617,"score":447.91257},{"pmid":32382463,"pmcid":"PMC7202588","title":"Rhabdomyolysis as a Presentation of 2019 Novel Coronavirus Disease.","text":["Rhabdomyolysis as a Presentation of 2019 Novel Coronavirus Disease.","An emerging viral infection is a global public health challenge. The development of modern, fast, and extensive transportation makes the outbreak hard to contain. Everyone is at risk, and the outbreak can rapidly turn into a pandemic crisis, like what we are currently facing for the 2019 novel coronavirus disease (COVID-19). Prompt diagnosis of the case is required to improve patients' prognosis and control of the outbreak. The common manifestations of COVID-19 include fever, cough, dyspnea, and malaise. However, patients may present with atypical symptoms that pose a diagnostic challenge. We report the first case of an elderly male who presented with rhabdomyolysis and later was diagnosed with COVID-19. Clinicians should be aware that rhabdomyolysis can be an initial presentation of COVID-19 or can occur at any time during the disease course. Patients with rhabdomyolysis should receive aggressive fluid administration to prevent acute kidney injury (AKI). However, COVID-19 patients are at risk of worsening oxygenation and acute hypoxemic respiratory failure from fluid overload. Therefore, cautious fluid administration is needed in COVID-19 patients with rhabdomyolysis.","Cureus","Suwanwongse, Kulachanya","Shabarek, Nehad","32382463"],"abstract":["An emerging viral infection is a global public health challenge. The development of modern, fast, and extensive transportation makes the outbreak hard to contain. Everyone is at risk, and the outbreak can rapidly turn into a pandemic crisis, like what we are currently facing for the 2019 novel coronavirus disease (COVID-19). Prompt diagnosis of the case is required to improve patients' prognosis and control of the outbreak. The common manifestations of COVID-19 include fever, cough, dyspnea, and malaise. However, patients may present with atypical symptoms that pose a diagnostic challenge. We report the first case of an elderly male who presented with rhabdomyolysis and later was diagnosed with COVID-19. Clinicians should be aware that rhabdomyolysis can be an initial presentation of COVID-19 or can occur at any time during the disease course. Patients with rhabdomyolysis should receive aggressive fluid administration to prevent acute kidney injury (AKI). However, COVID-19 patients are at risk of worsening oxygenation and acute hypoxemic respiratory failure from fluid overload. Therefore, cautious fluid administration is needed in COVID-19 patients with rhabdomyolysis."],"journal":"Cureus","authors":["Suwanwongse, Kulachanya","Shabarek, Nehad"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32382463","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.7759/cureus.7561","keywords":["ards","case report","corona virus","covid-19","covid-2019","novel corona virus","rhabdomyolysis"],"topics":["Case Report"],"weight":1,"_version_":1666267276715753473,"score":284.9399},{"pmid":32197060,"title":"Rhabdomyolysis as Potential Late Complication Associated with COVID-19.","text":["Rhabdomyolysis as Potential Late Complication Associated with COVID-19.","We describe a patient in Wuhan, China, with severe acute respiratory syndrome coronavirus 2 infection who had progressive pulmonary lesions and rhabdomyolysis with manifestations of lower limb pain and fatigue. Rapid clinical recognition of rhabdomyolysis symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection can be lifesaving.","Emerg Infect Dis","Jin, Min","Tong, Qiaoxia","32197060"],"abstract":["We describe a patient in Wuhan, China, with severe acute respiratory syndrome coronavirus 2 infection who had progressive pulmonary lesions and rhabdomyolysis with manifestations of lower limb pain and fatigue. Rapid clinical recognition of rhabdomyolysis symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection can be lifesaving."],"journal":"Emerg Infect Dis","authors":["Jin, Min","Tong, Qiaoxia"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32197060","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.3201/eid2607.200445","keywords":["2019 novel coronavirus disease","covid-19","china","sars-cov-2","wuhan","respiratory diseases","rhabdomyolysis","severe acute respiratory syndrome coronavirus 2","viruses","zoonoses"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138490044153856,"score":224.273},{"pmid":32473756,"title":"Neuroleptic malignant syndrome in patients with COVID-19.","text":["Neuroleptic malignant syndrome in patients with COVID-19.","We report the first two cases of Coronavirus Disease 2019 (COVID-19) who were receiving intensive care including favipiravir, and were clinically diagnosed with neuroleptic malignant syndrome (NMS) to focus attention on NMS in COVID-19 management. Case 1: A 46-year-old-man with acute respiratory distress syndrome (ARDS) caused by COVID-19 infection was being administered favipiravir. Fentanyl, propofol, and rocuronium were also given. On day 3, midazolam administration was initiated for deep sedation. On day 5, his high body temperature increased to 41.2 degrees C, creatine kinase level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS was suspected, and supportive therapy was initiated. High-grade fever persisted for 4days and subsided on day 9. Case 2: A 44-year-old-man with ARDS caused by COVID-19 infection was being treated with favipiravir. On day 5, risperidone was started for delirium. On day 7, his body temperature suddenly increased to 40.8 degrees C, his CK level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS diagnosis was confirmed, and both, favipiravir and risperidone were discontinued on day 8. On the same day, his CK levels decreased, and his body temperature normalized on day 9. Patients with COVID-19 infection frequently require deep sedation and develop delirium; therefore, more attention should be paid to the development of NMS in patients who are being administered such causative agents. The mechanism underlying the occurrence of NMS in COVID-19 patients treated with favipiravir remains unknown. Therefore, careful consideration of NMS development is necessary in the management of COVID-19 patients.","Am J Emerg Med","Soh, Mitsuhito","Hifumi, Toru","Isokawa, Shutaro","Shimizu, Masato","Otani, Norio","Ishimatsu, Shinichi","32473756"],"abstract":["We report the first two cases of Coronavirus Disease 2019 (COVID-19) who were receiving intensive care including favipiravir, and were clinically diagnosed with neuroleptic malignant syndrome (NMS) to focus attention on NMS in COVID-19 management. Case 1: A 46-year-old-man with acute respiratory distress syndrome (ARDS) caused by COVID-19 infection was being administered favipiravir. Fentanyl, propofol, and rocuronium were also given. On day 3, midazolam administration was initiated for deep sedation. On day 5, his high body temperature increased to 41.2 degrees C, creatine kinase level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS was suspected, and supportive therapy was initiated. High-grade fever persisted for 4days and subsided on day 9. Case 2: A 44-year-old-man with ARDS caused by COVID-19 infection was being treated with favipiravir. On day 5, risperidone was started for delirium. On day 7, his body temperature suddenly increased to 40.8 degrees C, his CK level elevated, and he developed tachycardia, tachypnea, altered consciousness, and diaphoresis. NMS diagnosis was confirmed, and both, favipiravir and risperidone were discontinued on day 8. On the same day, his CK levels decreased, and his body temperature normalized on day 9. Patients with COVID-19 infection frequently require deep sedation and develop delirium; therefore, more attention should be paid to the development of NMS in patients who are being administered such causative agents. The mechanism underlying the occurrence of NMS in COVID-19 patients treated with favipiravir remains unknown. Therefore, careful consideration of NMS development is necessary in the management of COVID-19 patients."],"journal":"Am J Emerg Med","authors":["Soh, Mitsuhito","Hifumi, Toru","Isokawa, Shutaro","Shimizu, Masato","Otani, Norio","Ishimatsu, Shinichi"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32473756","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ajem.2020.05.042","keywords":["covid-19","fever","neuroleptic malignant syndrome"],"topics":["Case Report"],"weight":1,"_version_":1668341932708855808,"score":204.04868},{"pmid":32473151,"title":"Laboratory Abnormalities in Children with Mild and Severe Coronavirus Disease 2019 (COVID-19): a pooled analysis and review.","text":["Laboratory Abnormalities in Children with Mild and Severe Coronavirus Disease 2019 (COVID-19): a pooled analysis and review.","Limited data exists to-date on the laboratory findings in children with COVID-19, warranting the conduction of this study, in which we pool the currently available literature data on the laboratory findings seen in children with mild and severe COVID-19. Following an extensive literature search, we identified 24 eligible studies, including a total of 624 pediatric cases with laboratory-confirmed COVID-19, which report data on 27 different biomarkers. We then performed a meta-analysis to calculate the pooled prevalence estimates (PPE) for these laboratory abnormalities in mild COVID-19. As data was too limited for children with severe COVID-19 to allow pooling, results were presented descriptively in a summary of findings table. Our data show an inconsistent pattern of change in the leukocyte index of mild and severe cases of COVID-19 in children. Specifically, changes in leukocyte counts were only observed in 32% of the mild pediatric cases (PPE: 13% increase, 19% decrease). In mild disease, creatine kinase-MB (CK-MB) was frequently elevated, with a PPE of 33%. In severe disease, c-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH) were frequently elevated. Based on data obtained from early COVID-19 studies, leukocyte indices in children appear inconsistent, differing from those reported in adults that highlight specific leukocyte trends. This brings into question the utility and reliability of such parameters in monitoring disease severity in the pediatric population. Instead, we suggest physicians to serially monitor CRP, PCT, and LDH to track the course of illness in hospitalized children. Finally, elevated CK-MB in mild pediatric COVID-19 cases is indicative of possible cardiac injury. This highlights the importance of monitoring cardiac biomarkers in hospitalized patients and the need for further investigation of markers such as cardiac troponin in future studies.","Clin Biochem","Michael Henry, Brandon","Benoit, Stefanie W","Helena Santos de Oliveira, Maria","Chin Hsieh, Wan","Benoit, Justin","Ballout, Rami A","Plebani, Mario","Lippi, Giuseppe","32473151"],"abstract":["Limited data exists to-date on the laboratory findings in children with COVID-19, warranting the conduction of this study, in which we pool the currently available literature data on the laboratory findings seen in children with mild and severe COVID-19. Following an extensive literature search, we identified 24 eligible studies, including a total of 624 pediatric cases with laboratory-confirmed COVID-19, which report data on 27 different biomarkers. We then performed a meta-analysis to calculate the pooled prevalence estimates (PPE) for these laboratory abnormalities in mild COVID-19. As data was too limited for children with severe COVID-19 to allow pooling, results were presented descriptively in a summary of findings table. Our data show an inconsistent pattern of change in the leukocyte index of mild and severe cases of COVID-19 in children. Specifically, changes in leukocyte counts were only observed in 32% of the mild pediatric cases (PPE: 13% increase, 19% decrease). In mild disease, creatine kinase-MB (CK-MB) was frequently elevated, with a PPE of 33%. In severe disease, c-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH) were frequently elevated. Based on data obtained from early COVID-19 studies, leukocyte indices in children appear inconsistent, differing from those reported in adults that highlight specific leukocyte trends. This brings into question the utility and reliability of such parameters in monitoring disease severity in the pediatric population. Instead, we suggest physicians to serially monitor CRP, PCT, and LDH to track the course of illness in hospitalized children. Finally, elevated CK-MB in mild pediatric COVID-19 cases is indicative of possible cardiac injury. This highlights the importance of monitoring cardiac biomarkers in hospitalized patients and the need for further investigation of markers such as cardiac troponin in future studies."],"journal":"Clin Biochem","authors":["Michael Henry, Brandon","Benoit, Stefanie W","Helena Santos de Oliveira, Maria","Chin Hsieh, Wan","Benoit, Justin","Ballout, Rami A","Plebani, Mario","Lippi, Giuseppe"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473151","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.clinbiochem.2020.05.012","keywords":["sars-cov-2","biomarkers","clinical chemistry","inflammation","pediatrics"],"topics":["Diagnosis"],"weight":1,"_version_":1668255193395888128,"score":194.13957}]}